THE GAME-CHANGING CANCER BLOOD TEST
ONE SAMPLE, ONE ANSWER: CANCER PRESENT? YES/NO
DETECTS ANY CANCER, IDENTIFIES 25+ TYPES BY TISSUE OF ORIGIN
FINDS TUMOURS AS SMALL AS 1mm ANYWHERE IN THE BODY
FALSE POSITIVES LESS THAN 1%
CLIA AND CAP ACCREDITED LAB
RESEARCHED IN THOUSANDS OF PATIENTS TO DATE
SHOULD I GET THE ONCOblot® TEST?
HOW DO I GET THE ONCOblot® TEST?
The ONCOblot® blood test was conceived and developed by the husband and wife team of Dr. D. James Morré and Dr. Dorothy M. Morré who are professors emeritus and emerita of Indiana’s Purdue University. Since 1978, Purdue University has been a National Cancer Institute-designated cancer research center. The ONCOblot® test looks for tiny amount of proteins called ENOX2 in the blood. These proteins are produced by cells only when they become cancerous, and are not produced by healthy cells. The ENOX2 proteins are shed into the circulation and can be detected through an advanced patented process. These proteins serve as highly sensitive markers to confirm the presence of cancer. ENOX2 stands for Ecto-Nicotinamide adenine dinucleotide OXidase disulfide-thiol exchanger-2.
What does the ONCOblot® test do?
The ONCOblot® blood test can detect a tiny amount of cancer anywhere in the body, whether it has spread or not. It is estimated this test can find as few as 2 million cancer cells, which roughly corresponds to a 1 to 2mm tumour – about the size of a pin head! Compare this to a mammogram which requires a tumour to contain about 100 – 1000 times more cells (7.5mm in size) before it will be reliably detected! Even if there is no tumour, but there are more than about 2 million cancer cells floating in the blood or lymphatic system, ONCOblot® will detect the cancer with great accuracy.
“Stage 0” cancers are also detected with high accuracy (like DCIS which is a localized cancer of the breast). What is even more impressive is that ONCOblot® also has a very low false-positive rate of less than 1% (the chance of telling you there is cancer in the body when there actually isn’t). This is extremely important because the test would not be useful if it frequently reported the presence of cancer when there was none.
In addition, ONCOblot® can identify the organ that the cancer came from (“tissue of origin”) without a scan or biopsy, with over 96% accuracy. If there are more cancer cells present, the accuracy of identifying the correct organ increases. More detailed information about the accuracy of ONCOblot® can be found on the FAQ page.
Who is the ONCOblot® test for?
The ONCOblot® blood test can be used for healthy people for ultra-early cancer detection, and also for patients with cancer or suspected cancer. A detailed list of recommended indications for using this test can be found below under Medicor Recommendations.
Why is ONCOblot® considered a “game changer” in cancer prevention?
ONCOblot® can detect tiny amounts of cancer anywhere in the body, non-invasively with a simple blood test. This ultra-early cancer detection is called secondary prevention, which refers to catching the cancer early when it is not nearly as dangerous. Preliminary research by the Morré team, as well as experience of the Medicor team confirms that affordable, non-toxic therapy can be used to effectively treat cancer when it is caught early enough. Many cancers normally considered deadly, when caught at such early stages, will be curable by conventional therapies and/or off-label gentle therapies*. If the cancer is not cured, it can often be transformed from a devastating life-threatening disease to a chronic condition like high blood pressure.
* It is well-accepted by medical doctors that earlier cancer detection increases the chance of cure. For example, Cancer Care Ontario states that 9 out of 10 cases of colon cancer can be cured if caught early enough.
How do I get the ONCOblot® test in Canada?
The test may be obtained through medical doctors, naturopathic doctors (ND)**, and other health professionals in Canada. Many health professionals are Medicor’s ONCOblot® partners, which means they are educated and equipped to perform the test. If your doctor, ND or other professional is not on the list of partners, please have them contact us. If you do not have a ND, we can help you find one. Your professional will arrange for a blood sample to be taken and shipped to the ONCOblot® lab. They will receive the test report in about 3 weeks and provide the result to you, with interpretation. An action plan can then be formulated.
If you are near the Medicor office, you may book an appointment to come in for a blood draw. Medcior staff will draw a blood sample and ship it to the ONCOblot® lab. We can draw blood from PICC lines and implanted ports if needed (there is a small additional fee for ports). Medicor will receive the test report in about 3 weeks, and provide the result to you with interpretation. An action plan can then be formulated.
** All naturopathic doctors in Ontario may now order this test through the Medicor office via a streamlined process that maintains compliance with the latest regulations.
If you fit any of the following conditions, we recommend speaking to a medical doctor or naturopathic doctor, or contacting us without delay to consider an ONCOblot® test:
- You were recently diagnosed with “cancer of unknown primary”
- You were treated for cancer and told it is cured or in remission (excluding basal cell skin cancer)
- You had a test / scan / biopsy suggesting cancer, but it was not definite
- You had a biopsy, but you want a second opinion
- There is suspicion of cancer / undiagnosed mass, but you refused a biopsy due to risks involved, or other reasons
- You have a close family member who has / had cancer, especially at a young age
- You have been diagnosed with a genetic mutation that is associated with increased cancer risk (for example BRCA gene)
- You have smoked or had significant carcinogen exposure in the past (including radiation or chemical exposure)
- You are at an age where cancer risk is starting to increase (for example over 40 or over 50)
Please note that some of these recommendations are considered “off-label”.